Avanos Medical (AVNS) Cash & Equivalents (2013 - 2026)

Avanos Medical (AVNS) has 14 years of Cash & Equivalents data on file, last reported at $65.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 32.37% year-over-year to $65.6 million; the trailing twelve-month figure through Mar 2026 stood at $65.6 million (down 32.37% YoY), and the FY2025 full-year result was $89.8 million, down 16.62% from the prior year.
• Cash & Equivalents fell to $65.6 million in Q1 2026, from $89.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $127.7 million in Q4 2022 to a low of $65.6 million in Q1 2026.
• A 5-year average of $94.5 million and a median of $92.2 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents advanced 27.97% in 2025 and sank 32.37% in 2026, its largest moves.
• Tracing AVNS's Cash & Equivalents over 5 years: stood at $127.7 million in 2022, then sank by 31.32% to $87.7 million in 2023, then climbed by 22.81% to $107.7 million in 2024, then decreased by 16.62% to $89.8 million in 2025, then declined by 26.95% to $65.6 million in 2026.
• Business Quant data shows AVNS's Cash & Equivalents at $65.6 million in Q1 2026, $89.8 million in Q4 2025, and $70.5 million in Q3 2025.